Welcome Guest
Home » Press Releases » The Growing Landscape of Biopharmaceutical Contract Manufacturing Market

The Growing Landscape of Biopharmaceutical Contract Manufacturing Market


Published : May 24, 2017

Roots Analysis has announced the addition of “Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017 - 2027” report to its list of offerings. The report provides an extensive study of the contract manufacturing market for biopharmaceuticals. It features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs.

 

Snehasish Das, the principal analyst, stated, “The development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. In addition, the costs associated with acquiring capabilities in this field are exorbitant and, therefore, it is difficult for companies with limited resources and finances to succeed by themselves. This has led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers”

 

One of the key focus areas of the study was to estimate size of the future opportunity for biopharmaceutical CMOs over the coming decade. The report provides market’s projections, segmented on the basis of commonly outsourced business operations, types of expression systems and key geographical regions. Amongst other things, the study also covers the following:

  • A review of the competitive market landscape and an industry analysis, based on geographical location, scale of operation, type of biologics manufactured, expression systems used, type of bioreactors used, mode of operation of bioreactors and bioprocessing capacity.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing  and packaging of biologics. Each profile provides an overview of the company, its financial performance, information on its manufacturing service and facilities, partnerships and recent developments.
  • A detailed discussion on the key enablers, including certain niche sub-segments, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical contract service providers.
  • A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the market. The analysis takes into consideration the average capacities of small, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research.
  • Information on other aspects of biopharmaceutical outsourcing, which include the growing number of collaborations, partnerships and investments in facility expansions.
  • Affiliated trends, key drivers  and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution.

 

Das further added, “Driven by increasing global demand and the rapidly expanding biopharmaceutical market, we expect the overall contract manufacturing market in the biopharmaceuticals domain to grow at an annualized rate of 8.7% between 2017 and 2027. The growth is likely to be higher in emerging markets of Asia and rest of the world.”

 

The report highlights the contributions of several players in the field, including the following:

  • 3P Biopharmaceuticals
  • Abzena
  • Albany Molecular Research
  • BioVectra
  • BioXcellence (Boehringer Ingelheim)
  • Celonic
  • Charles River Laboratories
  • ChemPartner
  • Cobra Biologics
  • CordenPharma
  • Cytovance Biologics
  • GE Healthcare
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • IDT Biologika
  • KBI BioPharma
  • Kemwell Biopharma
  • LFB Biomanufacturing
  • Meridian Life Science
  • Patheon
  • Pfizer CentreOne
  • PX'Therapeutics
  • Samsung BioLogics
  • Sanofi, CEPiA
  • Thermo Fisher Scientific
  • Vetter Pharma International

 

The opinions and insights discussed in this report were influenced by valuable inputs from senior stakeholders in the industry. The report features detailed transcripts of interviews held with Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies)

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market-2nd-edition-2017-2027/165.html

or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

Contact:

Gaurav Chaudhary

+1-604-595-4954
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Copyright © Roots Analysis. All Rights Reserved.
website security